Medicare Lab Test Payments: Upcoming Changes and Their Implications

Millions of Medicare beneficiaries may experience changes in the reimbursement process for common laboratory tests. This follows the release of preliminary 2027 payment rates by the Centers for Medicare & Medicaid Services (CMS). This release is based on updated private insurer payment data collected under the Protecting Access to Medicare Act (PAMA), which aims to align Medicare payments with market prices.

Current Payment Landscape

CMS found that Medicare has been paying approximately 16% more for laboratory services compared to private insurers. These changes could potentially save taxpayers around $1 billion annually. CMS Administrator Dr. Mehmet Oz stated that this move will help Medicare spend responsibly, ensuring rates reflect market realities and contribute to more informed pricing decisions across the healthcare system.

Role of Lab Testing

Lab tests are crucial in healthcare, including routine blood work, cholesterol panels, and advanced diagnostics like genetic and cancer testing. Although these new rates won’t immediately change out-of-pocket costs for most Medicare recipients, they could affect lab revenues significantly. Concerns include whether Medicare’s payment structure effectively represents the cost of providing testing services.

Potential Impact on Services

The preliminary payment rates, based on the Clinical Laboratory Fee Schedule (CLFS), suggest significant reductions. The largest decreases are expected in genomic sequencing (down 23%), molecular pathology (down 22%), and microbiology and immunology testing (both down 19.3%). Chemistry testing, which covers routine blood tests, could see a potential reduction of 16%, whereas specialized lab tests might face less impact.

These changes are part of the second full data collection cycle since PAMA was enacted in 2014. A new reporting cycle is scheduled for 2026, enabling CMS to use updated private payor data to propose 2027 rates. However, federal law will limit reductions for any test to no more than 15% annually through 2029. Therefore, larger reductions will be phased over several years.

Public and Industry Reactions

Public comments on the rates are being accepted for 30 days before final rates are published. Quest Diagnostics expressed concerns and highlighted flaws in the PAMA reporting system. They advocate for legislative reform through the RESULTS Act, claiming the current system does not collect representative private payor data.

Quest Diagnostics noted that a survey showed 96% of voters view lab testing as important to their healthcare needs, and 74% believe Congress should act to prevent further payment reductions. Over 130 Congress members and 70 patient and provider organizations support the legislation.

Challenges and Future Implications

Kevin Thompson, CEO of 9i Capital Group, remarked that Medicare’s costs spread across a broad spectrum, unlike private insurers that can set coverage parameters. Concerns arise about whether repeated reimbursement reductions might impact the availability of certain tests, particularly affecting smaller labs.

Next Steps

The public comment period will stay open for 30 days. CMS will review feedback and finalize the 2027 Clinical Laboratory Fee Schedule. Final rates are expected to be available in November. In the long term, there are concerns that the new rates might shift Medicare towards more private insurance-like operations, focusing on cost control through prior authorization.